Skip to content
Menu

Morgan Stanley Maintains Overweight on Sana Biotechnology, Raises Price Target to $13

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Maxwell Skor maintains Sana Biotechnology (NASDAQ:SANA) with a Overweight and raises the price target from $12 to $13.

Morgan Stanley analyst Maxwell Skor maintains Sana Biotechnology (NASDAQ:SANA) with a Overweight and raises the price target from $12 to $13.

Read at benzinga.com